cyp46a1-protein

Migration, Crosslink

📖

cyp46a1-protein

active

wiki page Created: 2026-04-02T07:19:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-cyp46a1-protein

📖 Wiki Page

protein1730 wordssynced 2026-04-02

CYP46A1 Protein — Cholesterol 24-Hydroxylase

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">cyp46a1-protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CYP46A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>cyp46a1-protein</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CYP46A1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer_disease" style="color:#ef9a9a">ALZHEIMER_DISEASE</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/dravet_syndrome" style="color:#ef9a9a">DRAVET_SYNDROME</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-2600483e" style="color:#ce93d8" title="Score: 0.61">CYP46A1 Overexpression Gene Therapy...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">107 edges</a></td>
</tr>
</table>

Introduction

...

CYP46A1 Protein — Cholesterol 24-Hydroxylase

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">cyp46a1-protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CYP46A1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>cyp46a1-protein</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CYP46A1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer_disease" style="color:#ef9a9a">ALZHEIMER_DISEASE</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/dravet_syndrome" style="color:#ef9a9a">DRAVET_SYNDROME</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-2600483e" style="color:#ce93d8" title="Score: 0.61">CYP46A1 Overexpression Gene Therapy...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">107 edges</a></td>
</tr>
</table>

Introduction

CYP46A1 (Cholesterol 24-Hydroxylase) is a neuron-specific cytochrome P450 enzyme that plays a critical role in maintaining brain cholesterol homeostasis. This enzyme catalyzes the conversion of cholesterol to 24(S)-hydroxycholesterol (24HC), the primary mechanism by which cholesterol is eliminated from the central nervous system (CNS). The discovery of CYP46A1 and its function has profoundly shaped our understanding of brain cholesterol metabolism and its relationship to neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease). [@bjorkhem2006] [@carter2007]

The brain contains approximately 25% of the body's total cholesterol but is isolated from peripheral cholesterol pools by the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). This isolation requires specialized mechanisms for cholesterol turnover within the CNS. CYP46A1 serves as the gateway for cholesterol export from the brain, as 24HC can cross the BBB and enter the systemic circulation for eventual clearance by the liver. This unique pathway makes CYP46A1 a pivotal enzyme at the intersection of cholesterol homeostasis, neuronal health, and neurodegenerative disease pathogenesis. [@bjorkhem2006] [@lutjohann2016]

Enzyme And Protein Context

Protein name: Cholesterol 24-Hydroxylase (CYP46A1)
Gene: [CYP46A1](/genes/cyp46a1)
UniProt ID: [Q9Y3D5](https://www.uniprot.org/uniprotkb/Q9Y3D5/entry)
PDB IDs: 5X29, 5UVW (crystal structures available)
Molecular weight: ~56 kDa
Subcellular location: Endoplasmic reticulum (neuronal cell bodies and dendrites)
Protein family: Cytochrome P450 family (CYP46A subfamily)
Expression: Primarily neuronal; highest expression in cortex, hippocampus, and cerebellum

CYP46A1 contains the conserved P450 structural features: an N-terminal transmembrane anchor for ER localization, a catalytic domain with heme-binding capability, and a substrate access channel that accommodates cholesterol. The enzyme exhibits high specificity for cholesterol as its substrate, converting it stereospecifically to 24(S)-hydroxycholesterol. This enzymatic activity is distinct from other P450 enzymes and reflects the specialized role of CYP46A1 in neuronal cholesterol homeostasis. [@elwood2019]

Molecular Functions In The Nervous System

Cholesterol Elimination from the Brain

The primary function of CYP46A1 is to facilitate cholesterol elimination from the brain:

24-Hydroxycholesterol production: CYP46A1 converts cholesterol to 24(S)-hydroxycholesterol through a hydroxylase reaction requiring NADPH and molecular oxygen

Blood-brain barrier crossing: Unlike cholesterol, 24HC is sufficiently polar to cross the BBB bidirectionally, allowing efflux from the brain

Liver clearance: Peripheral 24HC is metabolized by the liver and excreted in bile

This pathway accounts for the majority of cholesterol turnover in the adult brain, with estimates suggesting that approximately 1-2% of brain cholesterol is converted to 24HC daily. In contrast to peripheral cholesterol, brain cholesterol is not derived from circulating lipoproteins, making this autonomous pathway essential for neuronal health. [@bjorkhem2006] [@kotti2008]

Regulation by Nuclear Receptors

CYP46A1 expression is transcriptionally regulated by liver X receptors (LXRs):

LXR activation: LXRs (LXRα, LXRβ) sense oxysterol levels (including 24HC) and induce CYP46A1 expression, creating a negative feedback loop
PPAR involvement: Peroxisome proliferator-activated receptors (PPARs) also influence CYP46A1 expression
Cross-talk with cholesterol sensing: The LXR-CYP46A1 axis connects to SREBP-2 regulated cholesterol synthesis pathways

This regulatory network ensures that cholesterol homeostasis is maintained through coordinated regulation of synthesis (via HMGCR), uptake (via LDLR), and elimination (via CYP46A1). [@hubbert2007] [@kim2017]

24-Hydroxycholesterol Signaling

24-Hydroxycholesterol (24HC) is not merely a metabolic by-product but also serves as a signaling molecule:

LXR ligand: 24HC is a potent endogenous LXR agonist, amplifying its own production
Neuroprotective effects: At physiological concentrations, 24HC has anti-inflammatory and anti-oxidant properties
Biphasic effects: High concentrations of 24HC can become toxic, contributing to neurodegeneration

The dual nature of 24HC—protective at low concentrations and potentially damaging at high concentrations—highlights the importance of precise regulation of the CYP46A1 pathway. [@yang2020]

Role In Neurodegeneration

Alzheimer's Disease

CYP46A1 is strongly implicated in AD pathogenesis through multiple mechanisms:

Genetic Associations

Population studies have identified associations between CYP46A1 variants and AD risk:

The intronic rs4900440 polymorphism has been inconsistently associated with increased AD risk
Gene-gene interactions between CYP46A1 and APOE influence disease risk
Expression quantitative trait loci (eQTLs) in CYP46A1 may affect brain cholesterol metabolism

These genetic findings suggest that variations in CYP46A1 function can modulate AD susceptibility, though the effect size is modest. [@jiang2018] [@shibata2020] [@freund2020]

Biomarker Alterations

CYP46A1 activity is reflected in 24HC levels in cerebrospinal fluid (CSF) and plasma:

Elevated 24HC in AD: Multiple studies report increased CSF 24HC in AD patients compared to controls
Correlations with disease severity: CSF 24HC levels correlate with cognitive decline and neuroimaging markers
Predictive value: Some studies suggest 24HC may serve as an early biomarker, though specificity remains limited

The elevation in 24HC may reflect either increased enzyme activity as a compensatory response or neuronal loss releasing stored cholesterol pools. The interpretation remains an area of active investigation. [@popp2012] [@maudhoo2019] [@vanmierlo2019]

Cholesterol-Aβ Relationship

The relationship between CYP46A1, cholesterol, and amyloid pathology involves:

Cholesterol and amyloidogenesis: Elevated brain cholesterol increases amyloid precursor protein (APP) processing by β- and γ-secretases in lipid rafts

Membrane fluidity: Cholesterol-rich membranes favor amyloidogenic processing

APOE connection: APOE, the major AD risk gene, is involved in cholesterol transport and interacts with CYP46A1 pathways

Therapeutic rationale: Enhancing CYP46A1 activity may reduce brain cholesterol and thereby decrease Aβ production

These mechanistic links have driven interest in CYP46A1 as a therapeutic target for AD. [@carter2007] [@loera-valencia2019]

Tau Pathology

CYP46A1 also influences tau pathology through:

Cholesterol-mediated effects: Altered membrane cholesterol affects tau kinases and phosphatases

Direct 24HC effects: At high concentrations, 24HC can promote tau phosphorylation

Therapeutic approaches: CYP46A1 activation reduces tau pathology in preclinical models

The relationship between CYP46A1 and tau is bidirectional, as tau pathology itself can affect cholesterol homeostasis, potentially creating a vicious cycle. [@huang2021] [@testsi2021]

Parkinson's Disease

While less studied than in AD, CYP46A1 is implicated in PD:

Altered 24HC levels in PD CSF
Potential interactions with alpha-synuclein pathology
Modulation of dopaminergic neuron cholesterol homeostasis

Other Neurodegenerative Conditions

CYP46A1 involvement extends to:

Huntington's disease: CYP46A1 expression is altered in HD models and human tissue [@mastroberardino2009]
Multiple sclerosis: Demyelination affects brain cholesterol turnover
Frontotemporal dementia: Cholesterol dysregulation contributes to pathology

Disease Associations And Translational Relevance

Therapeutic Strategies

Multiple approaches target CYP46A1 for neurodegenerative disease treatment:

Direct CYP46A1 Activation

Small molecule activators: Several compounds have been identified that directly activate CYP46A1 enzymatic activity

Gene therapy: Viral vectors expressing CYP46A1 to enhance enzyme levels

LXR agonists: Indirect activation through LXR stimulation increases CYP46A1 expression

Preclinical studies with CYP46A1 activators have shown reduced amyloid and tau pathology in animal models. A small molecule activator has entered preclinical development for AD. [@huang2021] [@berwick2022]

24-Hydroxycholesterol-Based Approaches

24HC supplementation: Direct administration of 24HC to increase LXR activation

Derivatives: Modified 24HC analogs with improved properties

Combination approaches: 24HC with other therapeutic modalities

While 24HC itself has shown promise in preclinical models, the biphasic nature of its effects requires careful dosing strategies. [@yang2020]

LXR-Targeting Approaches

Since CYP46A1 is regulated by LXRs, LXR modulators represent an alternative approach:

Selective LXR modulators: Compounds that preferentially activate LXRβ (the brain-enriched isoform) to avoid peripheral side effects
Combination benefits: LXR activation also benefits lipid metabolism, inflammation, and other AD-relevant pathways

LXR agonists have shown efficacy in AD models but development has been slowed by side effects (liver steatosis, hypertriglyceridemia). Brain-selective approaches may overcome these limitations. [@loera-valencia2019]

Biomarker Applications

24HC measurements have potential clinical applications:

Diagnostic aid: Elevated CSF 24HC supports AD diagnosis
Disease monitoring: Changes in 24HC may reflect treatment response
Risk stratification: CYP46A1 genetic variants may inform risk assessment

However, standardization of assays and validation in larger cohorts are needed before clinical implementation. [@vanmierlo2019] [@lutjohann2016]

Challenges in Therapeutic Development

BBB penetration: Ensuring adequate brain exposure of systemically administered compounds

Enzyme activity vs. expression: Enhancing catalytic activity may differ from increasing protein levels

24HC toxicity: Avoiding excessive 24HC accumulation

Timing of intervention: Optimal treatment window relative to disease stage

Experimental Models And Methods

CYP46A1 knockout mice: Demonstrate the essential role of CYP46A1 in brain cholesterol elimination; show accumulation of cholesterol in the brain and neurological phenotypes. [@kotti2008]

Transgenic models: Overexpression of human CYP46A1 to assess effects on pathology

In vitro systems: Primary neurons, iPSC-derived neurons for mechanistic studies

Lipidomics: Measurement of cholesterol and oxysterol levels in brain, CSF, and plasma

Activity assays: Direct measurement of CYP46A1 enzymatic activity

Research Gaps And Future Directions

Temporal dynamics: When does CYP46A1 dysfunction begin relative to clinical symptoms?

Cell-type specificity: What determines which neuronal populations are most affected by CYP46A1 dysregulation?

Biomarker development: Can 24HC be validated as a clinical biomarker?

Combination therapies: How might CYP46A1-targeted approaches combine with anti-amyloid or other strategies?

Personalized medicine: How do CYP46A1 genotypes influence treatment response?

References

[Bjorkhem et al., Cholesterol 24-hydroxylase in brain (2006)](https://pubmed.ncbi.nlm.nih.gov/16580637/)

[Carter, AD and cholesterol pathological triad (2007)](https://pubmed.ncbi.nlm.nih.gov/17419803/)

[Jiang et al., CYP46A1 polymorphisms and AD risk (2018)](https://pubmed.ncbi.nlm.nih.gov/29427668/)

[Maudhoo et al., 24-Hydroxycholesterol in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30696762/)

[Popp et al., CSF 24-hydroxycholesterol in AD (2012)](https://pubmed.ncbi.nlm.nih.gov/22192608/)

[Loera-Valencia et al., Targeted brain cholesterol metabolism (2019)](https://pubmed.ncbi.nlm.nih.gov/30735689/)

[Vanmierlo et al., Age-related fluid biomarker for brain cholesterol (2019)](https://pubmed.ncbi.nlm.nih.gov/31162984/)

[Shibata et al., CYP46A1 genetic variants in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32134408/)

[Huang et al., CYP46A1 activation reduces Aβ (2021)](https://pubmed.ncbi.nlm.nih.gov/34518536/)

[Testsi et al., 24-Hydroxycholesterol and synaptic function (2021)](https://pubmed.ncbi.nlm.nih.gov/34792624/)

[Lutjohann & von Bergmann, 24-Hydroxycholesterol as biomarker (2016)](https://pubmed.ncbi.nlm.nih.gov/27584835/)

[Elwood et al., CYP46A1 expression in neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31020547/)

[Kotti et al., CYP46A1-deficient mice (2008)](https://pubmed.ncbi.nlm.nih.gov/18656459/)

[Hubbert et al., LXR regulation of CYP46A1 (2007)](https://pubmed.ncbi.nlm.nih.gov/17505817/)

[Kim et al., CYP46A1 and APOE interaction (2017)](https://pubmed.ncbi.nlm.nih.gov/28214090/)

[Freund et al., Brain cholesterol metabolism gene variants (2020)](https://pubmed.ncbi.nlm.nih.gov/32814025/)

[Berwick et al., CYP46A1-targeted small molecule (2022)](https://pubmed.ncbi.nlm.nih.gov/35447182/)

[Davies et al., Chronic CYP46A1 modulation in AD (2016)](https://pubmed.ncbi.nlm.nih.gov/26966186/)

[Yang et al., 24-Hydroxycholesterol as therapeutic agent (2020)](https://pubmed.ncbi.nlm.nih.gov/32387265/)

[Mastroberardino et al., CYP46A1 in HD (2009)](https://pubmed.ncbi.nlm.nih.gov/19578174/)

📖 View canonical wiki page →

Related Entities

CYP46A1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-cyp46a1-protein
kg_node_id	CYP46A1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d4f893434239
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cyp46a1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

204

Outgoing

214

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

cyp46a1-protein

CYP46A1 Protein — Cholesterol 24-Hydroxylase

Introduction

CYP46A1 Protein — Cholesterol 24-Hydroxylase

Introduction

Enzyme And Protein Context

Molecular Functions In The Nervous System

Cholesterol Elimination from the Brain

Regulation by Nuclear Receptors

24-Hydroxycholesterol Signaling

Role In Neurodegeneration

Alzheimer's Disease

Genetic Associations

Biomarker Alterations

Cholesterol-Aβ Relationship

Tau Pathology

Parkinson's Disease

Other Neurodegenerative Conditions

Disease Associations And Translational Relevance

Therapeutic Strategies

Direct CYP46A1 Activation

24-Hydroxycholesterol-Based Approaches

LXR-Targeting Approaches

Biomarker Applications

Challenges in Therapeutic Development

Experimental Models And Methods

Research Gaps And Future Directions

See Also

References

💬 Discussion